Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more
Market Cap & Net Worth: Valneva SE (INRLF)
Valneva SE (PINK:INRLF) has a market capitalization of $501.76 Million ($501.76 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #11005 globally and #4991 in its home market, demonstrating a -16.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Valneva SE's stock price $2.92 by its total outstanding shares 171833953 (171.83 Million).
Valneva SE Market Cap History: 2016 to 2025
Valneva SE's market capitalization history from 2016 to 2025. Data shows change from $642.66 Million to $501.76 Million (-2.66% CAGR).
Valneva SE Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Valneva SE's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.23x
Valneva SE's market cap is 2.23 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $642.66 Million | $94.06 Million | -$49.18 Million | 6.83x | N/A |
| 2017 | $611.73 Million | $105.29 Million | -$11.48 Million | 5.81x | N/A |
| 2018 | $601.42 Million | $113.03 Million | $3.26 Million | 5.32x | 184.26x |
| 2019 | $489.73 Million | $126.20 Million | -$1.74 Million | 3.88x | N/A |
| 2020 | $1.68 Billion | $110.32 Million | -$64.39 Million | 15.19x | N/A |
| 2021 | $4.73 Billion | $348.08 Million | -$73.42 Million | 13.58x | N/A |
| 2022 | $1.13 Billion | $361.30 Million | -$143.28 Million | 3.12x | N/A |
| 2023 | $871.20 Million | $153.71 Million | -$101.43 Million | 5.67x | N/A |
| 2024 | $378.03 Million | $169.58 Million | -$12.25 Million | 2.23x | N/A |
Competitor Companies of INRLF by Market Capitalization
Companies near Valneva SE in the global market cap rankings as of March 18, 2026.
Key companies related to Valneva SE by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Valneva SE Historical Marketcap From 2016 to 2025
Between 2016 and today, Valneva SE's market cap moved from $642.66 Million to $ 501.76 Million, with a yearly change of -2.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $501.76 Million | +32.73% |
| 2024 | $378.03 Million | -56.61% |
| 2023 | $871.20 Million | -22.83% |
| 2022 | $1.13 Billion | -76.12% |
| 2021 | $4.73 Billion | +182.15% |
| 2020 | $1.68 Billion | +242.11% |
| 2019 | $489.73 Million | -18.57% |
| 2018 | $601.42 Million | -1.69% |
| 2017 | $611.73 Million | -4.81% |
| 2016 | $642.66 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Valneva SE was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $501.76 Million USD |
| MoneyControl | $501.76 Million USD |
| MarketWatch | $501.76 Million USD |
| marketcap.company | $501.76 Million USD |
| Reuters | $501.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.